Alimera Sciences, Inc. (ALIM) News
Filter ALIM News Items
ALIM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALIM News Highlights
- For ALIM, its 30 day story count is now at 5.
- Over the past 23 days, the trend for ALIM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ALIM are HUM and MG.
Latest ALIM News From Around the Web
Below are the latest news stories about ALIMERA SCIENCES INC that investors may wish to consider to help them evaluate ALIM as an investment opportunity.
Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina NetworkILUVIEN or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathyATLANTA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that it has entered into an agreement with the Jaeb Center for Health Research |
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in IrelandReimbursement granted with no restrictions to the labelATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN ® (fluocinolone acetonide intravitreal implant) |
Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year. |
Is Humana (HUM) Stock Outpacing Its Medical Peers This Year?Here is how Humana (HUM) and Alimera Sciences (ALIM) have performed compared to their sector so far this year. |
Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual CongressPositive findings from the RIVER study and data on retreatment with ILUVIEN availableATLANTA, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg will be featured in more than 20 scientific abstracts d |
Why Fast-paced Mover Alimera Sciences (ALIM) Is a Great Choice for Value InvestorsAlimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen. |
Alimera Sciences (ALIM) Is a Great Choice for "Trend" Investors, Here's WhyAlimera Sciences (ALIM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year?Here is how Alimera Sciences (ALIM) and Centene (CNC) have performed compared to their sector so far this year. |
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual ConferenceATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will deliver a corporate presentation at the HC Wainwright 2nd Annual Ophthalmology Conference being held virtually on Wednesday, August 17, 2022. The |
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in PortugalReimbursement granted with no restrictions to the labelAlimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN® (fluocinolon |